Moderna: Oddo provides update following 'Omicron' variant

(CercleFinance.com) - Oddo believes that the emergence of the "Omicron" variant has put the spotlight back on vaccine players, particularly Moderna and BioNtech.


The technology of mRNA vaccines should be able to quickly adapt to these new challenges. While BioNtech has announced that it will be back in less than two weeks with "in-vitro" data on the protection of its vaccine, Moderna has presented a clear roadmap for its development strategy if the protection of its current vaccines is insufficient, Oddo said this morning.

Laboratory work is underway to analyse whether 100µg offers a better protection against Omicron. Moderna is already studying two multivalent booster candidates in the clinic that have been designed to anticipate mutations such as those that have emerged in the Omicron variant. Moderna will look at whether these two vaccine candidates have superior protection against Omicron. The last point is where Moderna will develop an Omicron-specific booster (mRNA1273.529), Oddo adds.

The broker confirms its Outperform rating on the stock with a target price of 440 dollars.


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.